All In Biotech

Drug Trial Radar · NCT01000506

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma

Last checked: Nov 20, 2026Latest source record: Jan 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 621 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

621

Actual

Start

Nov 1, 2009

Primary completion

Mar 23, 2012

Study completion Mar 23, 2012

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.

Conditions

  • Asthma

Interventions

  • Mepolizumab 750Biological

    Mepolizumab 750mg every four weeks by i.v.

  • Mepolizumab 250Biological

    Mepolizumab 250mg every four weeks by i.v.

  • Mepolizumab 75Biological

    Mepolizumab 75mg every four weeks by i.v.

  • Placebo salineDrug

    Placebo saline every four weeks by i.v.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Clinically Significant Exacerbations of Asthma Per YearTime frame: From randomization (Week 0) to Week 52 or early withdrawal (EW)

Locations

94 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Albany, Georgia

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Canton, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Hershey, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Boerne, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Mendoza, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina

  • GSK Investigational Site

    Mar del Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    New Lambton, New South Wales, Australia

  • GSK Investigational Site

    Adelaide, South Australia, Australia

  • GSK Investigational Site

    Clayton, Victoria, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Mississauga, Ontario, Canada

  • GSK Investigational Site

    Mississauga, Ontario, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Santiago, Chile

  • GSK Investigational Site

    Talcahuano, Chile

  • GSK Investigational Site

    Puente Alto - Santiago, Región Metro de Santiago, Chile

  • GSK Investigational Site

    Valparaíso, Valparaiso, Chile

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.